BBOT
BridgeBio Oncology Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.98
+0.90%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 186.0K | — | — | — | — |
| Gross Profit | (186.0K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 162.2M | 121.2M | 73.1M | 56.3M | — |
| SG&A Expense | 36.8M | 24.6M | 7.8M | 8.5M | 3.5K |
| General & Admin Expense | 36.8M | 24.6M | 7.8M | 8.5M | 3.5K |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (186.0K) | — | — | — | — |
| Total Operating Expenses | 198.8M | 145.8M | 80.9M | 64.8M | 3.5K |
| Cost and Expenses | 199.0M | 145.8M | 80.9M | 64.8M | 3.5K |
| Operating Income (EBIT) | (199.0M) | (145.8M) | (80.9M) | (64.8M) | (3.5K) |
| Non-Operating | |||||
| Interest Income | 15.4M | 11.3M | 6.4M | 72.0K | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 15.4M | 11.3M | 6.4M | 72.0K | — |
| Other Non-Op Income/Expense | 16.8M | 11.8M | 6.6M | 72.0K | — |
| Non-Operating Income (excl Interest) | (3.7M) | — | — | — | — |
| EBT (Pre-Tax Income) | (182.1M) | (134.0M) | (74.3M) | (64.7M) | (3.5K) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (182.1M) | (134.0M) | (74.3M) | (64.7M) | (3.5K) |
| Earnings from Cont. Ops | (182.1M) | (134.0M) | (74.3M) | (64.7M) | (3.5K) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (182.1M) | (134.0M) | (74.3M) | (64.7M) | (3.5K) |
| Per Share | |||||
| Basic EPS | ($1,232.82) | ($4.30) | ($5,756.41) | ($0.00) | $0.00 |
| Diluted EPS | ($709.70) | ($4.30) | ($5,756.41) | ($3.16) | ($0.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 80054 | 31.1M | 12903 | 20.5M | 20.5M |
| Diluted Shares Outstanding | 80054 | 31.1M | 12903 | 20.5M | 20.5M |
| Profitability Metrics | |||||
| EBITDA | (194.7M) | (145.2M) | (80.7M) | (64.7M) | (3.5K) |
| D&A | 561.0K | 610.0K | 208.0K | 92.0K | 3.5K |
| EBIT | (195.2M) | (145.8M) | (80.9M) | (64.8M) | (3.5K) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026